Goldman Sachs Initiates Coverage on DXCM with Buy Rating | DXCM Stock News
Goldman Sachs has initiated coverage on DexCom (DXCM) with a "Buy" rating, signaling a positive outlook for the company's continuous glucose monitoring sector. While no specific price target was declared, the initiation highlights confidence in DXCM's future growth potential and market position within the competitive healthcare industry. Wall Street analysts currently forecast an average target price of $99.73 for DXCM, with a consensus "Outperform" rating, and GuruFocus estimates a one-year fair value of $164.82.
Cardio Diagnostics Unveils New AI-driven Platform as Market Anticipates Growth
Cardio Diagnostics Holdings Inc. (CDIO) saw its stock rise by 41.96% following news of advancements in its AI-driven precision cardiovascular testing platforms and an upcoming investor call. Despite promising developments in precision medicine with tests like Epi+Gen CHD and PrecisionCHD, the company faces financial strain with negative free cash flow. The market is keenly watching how these AI innovations will translate into tangible financial growth and improved profitability.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q4 2025 Earnings Call Transcript
Tandem Diabetes Care (NASDAQ: TNDM) reported a record-setting Q4 and full-year 2025, surpassing $1 billion in sales and achieving double-digit growth with improved profitability. The company is actively modernizing commercial operations, expanding internationally, and introducing new technologies like Control-IQ+ and Mobi Tubeless. A significant strategic shift involves transitioning to a "pay-as-you-go" reimbursement structure in the pharmacy channel for the U.S. market, aiming to boost market expansion and long-term profitability despite facing near-term revenue headwinds in 2026.
SENS Eversense 365 Integrated With twiist Gains Full Availability
Senseonics Holdings, Inc. (SENS) announced the full availability of its Eversense 365 Continuous Glucose Monitoring (CGM) system, integrated with Sequel Med Tech’s twiist Automated Insulin Delivery (AID) system for U.S. type 1 diabetes patients. This integration is expected to boost customer adoption and sales for SENS, despite strong competition from larger players like Abbott and DexCom. The company also recently received CE Mark approval for Eversense 365 in Europe and reported strong preliminary Q4 2025 revenues, projecting significant growth for 2026.
Cardio Diagnostics Announces Investor Call Amidst Strategic Growth Plans
Cardio Diagnostics Holdings Inc. (CDIO) is holding an investor call to discuss strategic growth initiatives, including advancements in its AI-backed precision cardiovascular test. Despite reporting a net loss of $1.71M, the company maintains a robust 100% gross margin and a low debt-to-equity ratio of 0.03. The call aims to boost investor confidence and align narratives regarding the company's future in the evolving healthcare technology market.
PODD Q4 Deep Dive: Type 2 Diabetes Expansion and Innovation Drive Outperformance
Insulet Corporation (NASDAQ: PODD) reported strong Q4 CY2025 results, outperforming revenue expectations with a 31.2% year-on-year sales increase. The company's success is largely attributed to record new customer starts, particularly in type 2 diabetes management and international market expansion, driven by the Omnipod system. Insulet anticipates continued growth through further penetration of automated insulin delivery systems and ongoing product innovation, despite facing tougher year-over-year comparisons.
Bernstein cuts Insulet stock price target on competition concerns
Bernstein SocGen Group has lowered its price target for Insulet Corporation (NASDAQ:PODD) to $330 from $380, while maintaining an Outperform rating, due to increasing competition in the insulin pump market. Despite Insulet's strong revenue growth and financial health, investor concerns about competitive patch pumps and potential pricing pressure have led to an underperformance of its shares. The new price target reflects conservatism and investor worries, even as Bernstein sees upside potential from Type 2 diabetes execution and margin expansion.
Insulet Corporation (NASDAQ:PODD) Q4 2025 Earnings Call Transcript
Insulet Corporation (NASDAQ: PODD) reported its Q4 and full-year 2025 earnings, showcasing its 10th consecutive year of 20% or greater constant currency revenue growth. The company achieved record new customer starts in both U.S. and international markets, driven by the Omnipod system, particularly among those transitioning from multiple daily injections and expanding into the Type 2 diabetes segment. Insulet outlined future innovations including algorithm updates, expanded CGM integrations, the Omnipod Discover data platform, and the development of Omnipod 6 and a fully closed-loop system for Type 2 diabetes, while projecting continued top-tier growth and margin expansion for 2026.
Year-long glucose implant now links to insulin pump, easing life with type 1 diabetes
Senseonics (NASDAQ: SENS) and Sequel Med Tech announced the full U.S. availability of the twiist Automated Insulin Delivery (AID) system integrated with the Eversense 365 continuous glucose monitor (CGM). This combination offers people with type 1 diabetes a year-long CGM solution, reducing the need for frequent sensor changes and re-pairing while maintaining high accuracy. The twiist AID system is the first to be compatible with a year-long CGM, providing enhanced convenience and flexibility for long-term diabetes management.
The 5 Most Interesting Analyst Questions From DexCom's Q4 Earnings Call
DexCom's Q4 2025 earnings call highlighted strong performance, driven by the G7 15-day sensor system and international expansion. Analysts focused on long-term growth prospects, Medicare coverage for type two non-insulin users, the G7 sensor's margin contributions, and factors influencing revenue growth guidance. Management expressed optimism about future expansion and continued high utilization rates.
P/E Ratio Insights for DexCom
DexCom Inc. (NASDAQ: DXCM) is trading at $70.52, up 0.13% in the current session, but has seen a 2.33% decrease in the past month and a 21.17% decrease over the past year. The company's P/E ratio of 33.7 is lower than the industry aggregate of 42.66 for Health Care Equipment & Supplies, which could suggest the stock is undervalued or that shareholders expect lower future performance compared to its peers. Investors are advised to consider the P/E ratio alongside other financial metrics and qualitative analysis for informed decision-making.
Medical Device Company Exceeds Expectations with Insulin Pump Sales Growth
Insulet Corporation, a medical technology company, exceeded Wall Street expectations in the fourth quarter due to strong sales of its tubeless insulin delivery devices, particularly the Omnipod 5 system. The company reported a 31% revenue increase, achieved $781.8 million in Omnipod sales, and announced a $350 million boost to its stock repurchase program. Insulet projects significant revenue and adjusted per-share profit growth for 2026, signaling a positive outlook for investors.
Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues
Insulet (PODD) reported a strong Q4 earnings beat, with an adjusted EPS of $1.55 against an estimate of $1.46, and revenue of $783.8 million, surpassing forecasts. This performance was driven by the successful adoption of its Omnipod 5 Automated Insulin Delivery system and its expansion into the Type 2 diabetes market. The company projects 20-22% constant currency revenue growth for the upcoming year, fueled by strategic international expansion, new sensor integrations, and upcoming algorithm updates for its Omnipod 5 system.
Beta Bionics (BBNX) Q4 2025 Earnings Transcript
Beta Bionics (BBNX) reported strong Q4 and full-year 2025 financial results, with net sales up 54% year-over-year to $100.3 million and Q4 revenue increasing 57% to $32.1 million, driven by patient adoption and pharmacy channel growth. The company also provided 2026 guidance, expecting continued revenue growth between $130 million and $135 million, alongside strategic expansions in its sales force and ongoing R&D for its Mint patch pump and bihormonal system. Beta Bionics addressed an FDA warning letter concerning complaint handling and quality systems, asserting remediation efforts are on track and do not impact product launch timelines.
Earnings To Watch: iRhythm (IRTC) Reports Q4 Results Tomorrow
iRhythm Technologies (IRTC) is set to report its Q4 results this Thursday after market close. Analysts expect revenue growth of 22.9% year-on-year to $202 million and adjusted earnings of $0.06 per share. The company has a strong history of beating revenue estimates, and its stock is currently trading below the average analyst price target.
Dexcom G6 Glucose Monitor Lawsuit Claims Manufacturer’s Device Modifications Resulted in Teen’s Death
A wrongful death lawsuit has been filed against Dexcom by a Colorado father, alleging that unauthorized modifications to the Dexcom G6 continuous glucose monitoring system led to the death of his 18-year-old son, Jake Burdick. The lawsuit claims that Dexcom replaced an FDA-approved sensor coating with a cheaper alternative and updated the software without regulatory approval, resulting in less reliable sensors and a failure to provide critical glucose alerts. The FDA later cited Dexcom for these unauthorized changes and design failures following Jake's death from an undetected hyperglycemic episode.
Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow
Insulet Corporation (NASDAQ:PODD) is scheduled to report its Q4 earnings this Wednesday morning, with analysts anticipating a 28.6% year-over-year revenue growth to $768.2 million and adjusted earnings of $1.46 per share. The insulin delivery company has a strong record of exceeding revenue estimates, doing so every quarter for the past two years. Despite recent market underperformance in the healthcare equipment and supplies segment, Insulet's stock trades significantly below its average analyst price target.
Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow
Insulet Corporation (NASDAQ:PODD) is set to report its Q4 earnings on Wednesday morning. Analysts expect revenue growth of 28.6% year-on-year to $768.2 million and adjusted earnings of $1.46 per share. The company has a history of exceeding revenue expectations, and its peers ResMed and DexCom have also reported solid Q4 results, though the healthcare equipment and supplies sector has generally underperformed recently.
Earnings To Watch: Insulet (PODD) Reports Q4 Results Tomorrow
Insulet Corporation (PODD) is set to report its Q4 earnings tomorrow, with analysts expecting a 28.6% year-on-year revenue increase to $768.2 million and adjusted earnings of $1.46 per share. The company has a strong track record of beating revenue estimates, and although the healthcare equipment sector has underperformed recently, Insulet's stock is trading significantly below its average analyst price target.
What DexCom (DXCM)'s Margin Beat And Reaffirmed 2026 Outlook Means For Shareholders
DexCom (DXCM) reported strong Q4 and full-year 2025 results, exceeding revenue and net income expectations, and improving operating margins. The company also reaffirmed its 2026 revenue guidance of US$5.16–US$5.25 billion and highlighted advancements in AI-enhanced products like Stelo and the G7 15-day CGM system. This performance strengthens DexCom's investment narrative, particularly concerning continuous glucose monitoring adoption and reimbursement, though future pricing pressure and competition remain key risks.
Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV
Healthcare stocks showed strength before the Presidents Day holiday, with the Health Care Select Sector SPDR Fund (XLV) rising 1.1% on Friday. This was primarily driven by strong performances from Dexcom and Moderna following positive earnings reports and guidance. Investors are seeking steadier places to park money amidst "AI disruption" anxiety, while also keeping an eye on policy and litigation headlines.
DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook
DexCom Inc. (DXCM) reported strong Q4 2025 earnings with $1.26 billion in revenue, surpassing Wall Street expectations and showing 13% year-over-year growth. This performance was driven by robust sales of G7 and the new Stelo system, culminating in full-year 2025 revenue of $4.662 billion. The company also reiterated its 2026 revenue guidance, projecting $5.16 billion to $5.25 billion, fueled by continued market expansion and product advancements.
Altria Could Shatter Its 52-Week High: This Dividend King Beckons With a 6.4% Yield
Altria (MO) stock has risen 16% in 2026, offering a 6.4% dividend yield, and is poised to surpass its 52-week high. The company boasts 57 consecutive years of dividend increases, backed by strong profitability from its core tobacco business and rapid growth in its on! oral nicotine pouch shipments, which now dominate over 55% of the oral tobacco market. Despite challenges in traditional cigarette sales and e-vapor products, Altria's focus on smoke-free alternatives and consistent cash flow make it a reliable choice for income-focused investors.
The DexCom, Inc. (NASDAQ:DXCM) Yearly Results Are Out And Analysts Have Published New Forecasts
DexCom, Inc. (NASDAQ:DXCM) recently released its yearly results, with revenues of US$4.7 billion and EPS of US$2.09, both aligning with analyst expectations. Following these results, analysts have re-affirmed their forecasts for 2026, predicting revenues of US$5.23 billion and EPS of US$2.44, with the consensus price target remaining at US$85.46. Despite anticipated slower revenue growth compared to historical performance, DexCom is still expected to outpace the industry.
DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook
DexCom Inc. (DXCM) reported robust Q4 2025 earnings, surpassing Wall Street expectations with $1.26 billion in revenue, driven by strong sales of G7 and the new Stelo system. For the full year 2025, the company's revenue reached $4.662 billion, exceeding guidance. DexCom reiterated its 2026 revenue guidance, citing continued market expansion and product innovation.
DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook
DexCom Inc. (DXCM) reported strong Q4 2025 earnings with $1.26 billion in revenue, exceeding Wall Street expectations, and 13% year-over-year growth fueled by G7 and Stelo sales. For the full year 2025, revenue hit $4.662 billion, surpassing guidance, leading management to reiterate optimistic 2026 revenue guidance of $5.16 billion to $5.25 billion. The company attributes its success to product advancements, market expansion, and manufacturing optimizations, while also expanding access to CGM systems.
10 Best Medical Technology Stocks to Invest In
The article highlights DexCom Inc. (NASDAQ: DXCM) as one of the best medical technology stocks to invest in, detailing its strong Q4 2025 earnings with revenue of $1.26 billion and 13% year-over-year growth. DexCom's success was attributed to robust sales of its G7 and over-the-counter Stelo systems, exceeding both revenue and EPS expectations. The company also provided a positive outlook for 2026, forecasting continued revenue growth driven by market expansion and new features.
DexCom (DXCM) Margin Expansion To 17.9% Reinforces Bullish Earnings Narratives
DexCom (DXCM) concluded FY 2025 with strong fourth-quarter revenue of US$1.3 billion and a significant increase in trailing net profit margins from 14.3% to 17.9%, alongside 45.1% earnings growth. While analysts anticipate slower revenue and earnings growth rates for the future, the company's current P/E of 32.2x is below the peer average. The article discusses both bullish arguments, such as expanding reimbursement and CGM adoption, and bearish concerns like potential CMS competitive bidding and rising competition impacting future margins.
GrabAGun digital holdings COO sells $14k in stock
Matthew W. Vittitow, COO of GrabAGun Digital Holdings Inc. (NASDAQ: PEW), sold 5,012 shares of common stock totaling $14,133 to cover tax obligations related to vested restricted stock units. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan. This news follows other recent developments for GrabAGun, including accepting cryptocurrency payments and strategic partnerships.
10 Best Medical Technology Stocks to Invest In
This article highlights STERIS plc (NYSE: STE) as one of the best medical technology stocks to invest in, noting its strong Q3 FY2026 financial results. STERIS exceeded revenue expectations and matched profit forecasts, demonstrating significant year-over-year growth and reaffirming its full-year guidance. The company, which specializes in infection prevention and procedural support, showcased robust organic revenue growth driven by demand across various business lines.
Broadcom (NASDAQ: AVGO) Stock Price Prediction and Forecast 2026-2030 (Feb 2026)
This article provides a stock price prediction and forecast for Broadcom (NASDAQ: AVGO) from 2026 to 2030, highlighting its strong position in the semiconductor and software sectors due to AI demand and strategic acquisitions. The authors anticipate significant growth, with the stock potentially more than doubling its current price by 2030, driven by AI networking demand, VMware integration, and robust financial performance. The forecast includes specific revenue, EPS, and price targets for each year through 2030.
Supercom stock rises after securing new Louisiana monitoring contract
Supercom Ltd (NASDAQ:SPCB) saw its stock rise by 2.6% after announcing a new electronic monitoring service contract in Louisiana, marking its entry into its 16th U.S. state. The company will transition an existing provider's GPS tracking operations to its PureSecurity™ platform, replacing a previous vendor. This contract operates on a recurring revenue model and is SuperCom’s 17th new service provider partnership since mid-2024, expanding its U.S. footprint.
DexCom’s AI Stelo Upgrade Faces Valuation Questions After Share Declines
DexCom is introducing AI-driven upgrades to its Stelo glucose monitoring platform, including enhanced Smart Food Logging and a new Daily Insights interface, aimed at boosting consumer engagement. Despite these innovations, DexCom's shares have declined 19% over the past year and 41.9% over three years, raising valuation concerns. The stock is currently trading above its estimated fair value and analysts are watching how these new features will impact user engagement and financial performance.
12 Best Mid Cap AI Stocks to Buy According to Hedge Funds
This article highlights JFrog Ltd. (NASDAQ:FROG) as a key mid-cap AI stock favored by hedge funds, noting its strong growth profile and potential benefits from increased AI adoption. Analysts from Robert W. Baird and Bank of America Securities have reaffirmed Buy ratings, citing the company's role in managing binaries for AI-generated code and its accelerating cloud revenue. JFrog's tools for software supply chain management and risk mitigation position it as a direct beneficiary of the expanding AI market.
Key facts: DexCom reports $2.8B profit; Wells Fargo cuts price target
DexCom, Inc. reported a gross profit of $2.8 billion for 2024, a 15% increase from the previous year, despite a dip in gross profit margin due to supply chain issues. As a result, Wells Fargo and Canaccord Genuity have both lowered their price targets for DXCM. DexCom is also expanding its product line with Smart Basal and anticipates increased insurance coverage for type 2 diabetes, which could broaden its market.
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth
DexCom (DXCM) reported strong fourth-quarter and full-year 2025 results, beating analyst estimates for both earnings and revenue, driven by robust G7 rollout and international expansion. Despite this positive financial performance and optimistic 2026 guidance, the company's stock experienced a slight fall in after-hours trading, and has seen a significant decline over the past six months. Key growth drivers include solid customer demand, expanding access for type 2 non-insulin users, and advancements in its G7 15 Day system and future product pipelines.
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth
DexCom (DXCM) reported strong fourth-quarter and full-year 2025 results, beating adjusted EPS and revenue estimates, driven by the G7 rollout and international expansion. Despite the positive financial performance, the stock fell by almost 1.1% in after-hours trading. The company also reiterated its 2026 revenue guidance, anticipating significant growth and margin expansion.
Dexcom seeks expanded Medicare coverage of CGMs for Type 2 diabetes
Dexcom is actively pursuing expanded Medicare coverage for its continuous glucose monitors (CGMs) for individuals with Type 2 diabetes who do not use insulin, with CEO Jake Leach anticipating a coverage proposal in the first half of 2026. The company is generating real-world data and has a randomized controlled trial planned to support this expansion, building on recent commercial coverage and updated American Diabetes Association guidelines. Dexcom also recently launched a 15-day G7 sensor, which has contributed to increased demand.
Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations
Dexcom reported strong 2025 revenues of $4.66bn, driven by demand for its continuous glucose monitoring systems, with Q4 2025 earnings at $1.26bn. Despite this, the company's 2026 revenue forecast of $5.16bn to $5.25bn, while showing double-digit growth, fell slightly below analysts' expectations. CEO Jake Leach outlined plans for 2026, including increasing awareness of the new G7 15-day device, enhancing customer experience, and expanding international market share, particularly with the Smart Basal launch.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. (DXCM) shares rose 7.59% to $70.02 on Friday, ending a three-day losing streak, amidst a generally positive trading day for the stock market. Both the S&P 500 Index and the Dow Jones Industrial Average modestly increased. This performance highlights DexCom's strong individual showing relative to its competitors.
Is the YieldMax AAPL Option Income Strategy ETF’s (APLY) 70% Yield Real or Misleading?
The article examines the YieldMax AAPL Option Income Strategy ETF (APLY), which boasts a 70.75% yield but relies on option strategies like covered calls. While the high yield is attractive, the ETF comes with 1.06% in annual operating expenses and its share price is prone to decline as distributions are paid out. The author concludes that while the yield isn't misleading, it is risk-prone due to share price weakness, suggesting that direct ownership of Apple stock might be a more prudent investment for many.
DexCom (NASDAQ:DXCM) Stock Price Up 8.4% on Earnings Beat
DexCom's stock price surged 8.4% after the company successfully beat Q4 earnings and revenue estimates. Analysts have reacted positively, with Mizuho and BTIG raising their price targets, contributing to a consensus target around $85.05. Despite an elevated valuation and past underperformance, the company's strong demand for continuous glucose monitors and an AI upgrade for its Stelo product suggest potential for continued growth.
DexCom, Inc. (NASDAQ:DXCM) Q4 2025 Earnings Call Transcript
DexCom, Inc. reported strong Q4 and full-year 2025 results, with revenue exceeding guidance and EPS beating expectations. The company highlighted the successful broad rollout of its DexCom G7 15-day system and the upcoming launch of DexCom Smart Basal. CEO Jacob Steven Leach emphasized continued innovation, improved customer experience, and significant international expansion opportunities, particularly anticipating broader access for type 2 non-insulin users in the US and globally.
The iShares AI Innovation and Tech Active ETF is the Pefect Way to Ride the Agentic Wave
The article highlights the iShares AI Innovation and Tech Active ETF (BAI) as an ideal investment to navigate the "agentic AI wave" and the recent "SaaSpocalypse" that has negatively impacted software companies. It praises BAI's active management approach and its significant exposure to chip-related companies, which are currently benefiting most from the AI boom. The ETF also offers geographical diversification beyond the U.S., making it a robust option for investors seeking to capitalize on AI innovation.
Soleus Adds a Significant Number of Celcuity Shares
Soleus Capital Management L.P. significantly increased its stake in Celcuity (NASDAQ: CELC) by purchasing an additional 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This move makes Celcuity Soleus's third-largest holding, despite the biotechnology company currently generating no revenue and experiencing a remarkable 745% stock price increase over the last year. The article highlights Celcuity's focus on cancer diagnostics and therapies but also cautions investors about the inherent risks due to its lack of current revenue.
DexCom (NASDAQ:DXCM) Price Target Raised to $90.00
Mizuho has increased its price target for DexCom (NASDAQ:DXCM) to $90.00, maintaining an "outperform" rating and suggesting a 38% upside. This follows DexCom's strong Q4 performance, where it surpassed EPS and revenue estimates, reporting $0.68 EPS and $1.26 billion in revenue. Despite positive analyst sentiment, the stock faces near-term headwinds including trading below moving averages and a high P/E ratio.
Wells Fargo Adjusts DexCom Price Target to $85 From $93, Maintains Overweight Rating
Wells Fargo has lowered its price target for DexCom (DXCM) to $85 from $93, while reiterating an "Overweight" rating on the stock. This adjustment reflects an updated outlook on the medical equipment company, which specializes in continuous glucose monitoring systems. The news follows DexCom's recent Q4 2025 earnings report, where it beat quarterly estimates due to strong demand for its glucose monitors.
Stifel reiterates Buy rating on DexCom stock, maintains $85 price target
Stifel maintained its Buy rating and an $85.00 price target for DexCom (NASDAQ:DXCM) following the company's recent earnings report, noting that the Q4 results contained few surprises. The firm highlighted management's optimistic tone regarding strong sell-through and future international continuous glucose monitoring (CGM) market growth, with non-U.S. sales potentially surpassing domestic revenue. DexCom's solid financial performance, including 14.21% revenue growth and a 59% gross profit margin, supports this outlook, with potential catalysts in 2026 including T2NIT Medicare coverage and new product introductions.
Stifel reiterates Buy rating on DexCom stock, maintains $85 price target
Stifel maintained its Buy rating and $85 price target on DexCom (NASDAQ:DXCM) following the company's recent strong fourth-quarter earnings report. Despite a post-earnings stock dip, Stifel remains optimistic due to strong sell-through, positive international market outlook, and potential catalysts like Medicare coverage and new products, naming DexCom a top pick in the diabetes sector. The firm's target aligns with InvestingPro's Fair Value, suggesting the stock may be undervalued.
Freedom Capital Markets initiates Natural Grocers stock with Buy rating
Freedom Capital Markets initiated coverage on Natural Grocers (NYSE:NGVC) with a Buy rating and a price target of $36.00, citing the company's attractive P/E ratio, defensive position in food retail, and disciplined business model. Natural Grocers recently reported a 14% increase in Q1 2026 EPS and a 1.6% rise in net sales, alongside plans to expand into its 22nd state with a new store in Wisconsin. The firm believes these factors position Natural Grocers for steady earnings growth and attractive risk-adjusted returns.
